Hengrui Pharma signs deal with Braveheart Bio for HRS-1893
The deal involves an initial payment of $65m from Braveheart to Hengrui, split equally between cash and equity in Braveheart.
08 September 2025
08 September 2025
The deal involves an initial payment of $65m from Braveheart to Hengrui, split equally between cash and equity in Braveheart.
In a hearing with many fiery exchanges, RFK Jr defended his position on vaccine policies, CDC leadership, and Covid-19 legacy.
Phoenix will be supplied with rimiducid by MD Anderson as part of the cross-licensing agreement.
The new framework comes amid frail times for rare disease drug research in the US.
Vimkunya will now be available in the UK following a 170% national increase in travel-related chikungunya cases.
The approval was based on results from the Phase III ASPEN study and Phase II WILLOW study.
The alert is part of a growing trend in the prevalence of counterfeit and unregulated GLP-1RAs.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.